MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

uniQure NV

Open

14.31 -3.38

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.74

Max

14.9

Schlüsselkennzahlen

By Trading Economics

Einkommen

-29M

-73M

Verkäufe

2.9M

5.2M

EPS

-1.442

Gewinnspanne

-1,403.199

Angestellte

209

EBITDA

-28M

-53M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+145.44% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

129M

719M

Vorheriger Eröffnungskurs

17.69

Vorheriger Schlusskurs

14.31

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

uniQure NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Dez. 2024, 15:18 UTC

Wichtige Markttreiber

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Peer-Vergleich

Kursveränderung

uniQure NV Prognose

Kursziel

By TipRanks

145.44% Vorteil

12-Monats-Prognose

Durchschnitt 35 USD  145.44%

Hoch 70 USD

Tief 18 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für uniQure NV – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

8.92 / 14.42Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.